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Two decades have passed since the discovery of the tumor suppressor, PTEN. Amultitude of biological func-
tions have since been revealed, suggesting potential therapeutic applications for both PTEN activation (e.g.,
cancer) and inhibition (e.g., neuroregeneration). Nevertheless, PTEN’s therapeutic suitability has been called
into question due to its ‘‘risky’’ profile as a tumor suppressor. To evaluate PTEN function and its various roles
in disease a number of molecules have so far been developed. However, intrinsic problems associated with
phosphatase inhibition and PTEN’s complex regulation via post-translational modifications hinder straight-
forward access to selective modulators. For this reason, central questions associated with PTEN targeting
remain unanswered. In this perspective, we summarize current PTEN-targeting strategies and discuss po-
tential approaches to modulate its functional dose, considering all stages of PTEN biogenesis from direct
protein modulation to the targeting of relevant miRNAs as well as the PTEN gene and mRNA.Introduction
In 1997, a phosphatase-encoding gene, which upon deletion
induced aggressive tumorigenesis across kidney, breast and
prostate cell lines (Li et al., 1997; Steck et al., 1997), was iden-
tified. Phosphatase and Tensin Homolog on Chromosome 10
(PTEN) was quickly validated as an essential tumor suppressor
and over the course of the next two decades, characterized as
a ubiquitous modulator of cell growth and proliferation, fea-
tures mainly associated with its lipid phosphatase activity (Sal-
mena, 2016). After p53, PTEN is the second most commonly
mutated tumor suppressor in human cancer with some 30%
of tumors harboring somatic, PTEN mutations (Nakamura
et al., 2000; Simpson and Parsons, 2001). In addition, PTEN
dysregulation has been implicated not only in cancer but in a
wide variety of other non-oncogenic illnesses, including Alz-
heimer’s disease and autism (Knafo et al., 2016; Zhou and
Parada, 2012).
PTEN at the 10q23 locus is under the control of various tran-
scription factors such as EGR-1, p53, ATF2, PPARg (Correia
et al., 2014). Other proteins such as HES-1, C-Jun, and
NF-kB transcriptionally repress PTEN, while an additional layer
of epigenetic repression has also been reported to occur via
methylation of the PTEN promoter or via histone deacetylase-
containing complexes such as PML/RARa or NuRD/Mi2 (Cor-
reia et al., 2014; Lu et al., 2009; Noguera et al., 2016). Upon
transcription, PTEN mRNA undergoes splicing and is translo-
cated to the cytosol where it becomes a target for miRNA-
guided degradation (Sharrard and Maitland, 2000) (Figure 1).
Prominent PTEN-targeting miRNAs include proto-oncogenic
miR-19, miR-21, and miR-221 (Garofalo et al., 2009; Meng
et al., 2007; Olive et al., 2009). As an added layer of regulatory
complexity, several long non-coding RNAs (lncRNAs) purport-
edly sequester miRNAs from binding to PTEN mRNA, however
the biological significance of this mechanism remains contro-C
versial (Poliseno et al., 2010; Tay et al., 2011; Thomson and
Dinger, 2016).
PTEN is a protein containing 403 amino acids with a number of
additional proteoforms (Malaney et al., 2017). It fulfills itsmain tu-
mor suppressor activity at the plasma membrane by dephos-
phorylating phosphatidylinositol (3,4,5)-trisphosphate (PIP3,
Figure 1) to phosphatidylinositol-4,5-bisphosphate (PIP2) (Song
et al., 2012) thereby counteracting phosphoinositide 3-kinase
(PI3K) signaling (Jean and Kiger, 2014). Among others (Rowland
et al., 2011), PTEN inhibits AKT-dependent pathways such as
GSK3 (metabolic stimulation), FOXO (cell cycle progression),
BAD/MDM2 (cell survival), and themTOR axis (protein synthesis)
(Song et al., 2012). Critically, PTEN’s phosphatase activity and
subcellular localization are dynamically controlled by post-trans-
lational modifications (PTMs) (Bermúdez Brito et al., 2015), ex-
amples include phosphorylation, ubiquitination, oxidation, acet-
ylation, and sumoylation (Bermúdez Brito et al., 2015).
Phosphorylation of PTEN’s C-tail promotes electrostatic interac-
tions with its membrane-binding region, resulting in a conforma-
tionally closed state with reduced membrane association and
phosphatase activity (Silva et al., 2008) (Figure 1). While not fully
elucidated, autodephosphorylation contributes to the conforma-
tional re-opening of PTEN (Rahdar et al., 2009; Tibarewal et al.,
2012). Monoubiquitination by NEDD4-1 promotes nuclear
import, whereas polyubiquitination by the same enzyme or
others marks PTEN for proteasomal degradation (Leslie et al.,
2016). Certain PTMs can also mediate direct inhibition of phos-
phatase activity as seen when PTEN’s catalytic cysteine is
oxidized by reactive oxygen species (Cho et al., 2004; Lee
et al., 2015).
Aside from PIP3 dephosphorylation and autodephosphory-
lation, PTEN recognizes other protein substrates and is
involved in a number of protein-protein interactions (PPIs)
(Myers et al., 1997; Worby and Dixon, 2014). PPIs involvingell Chemical Biology 25, January 18, 2018 ª 2017 Elsevier Ltd. 19
Figure 1. Schematic Overview of PTEN Biogenesis and Regulation
Located at chromosome 10q23, PTEN is transcribed under the influence of various transcription factors, including EGR-1, p53 and PPARg. Upon transcription,
PTEN mRNA is spliced and becomes a target for a number of miRNAs, including miR-21. Translation yields the PTEN protein, a membrane-active lipid phos-
phatase that primarily dephosphorylates PIP3 to provide PIP2 thereby antagonizing AKT signaling. Membrane-localized PTEN also engages in a number of
protein-protein interactions (PPIs) with PDZ-containing proteins through its C-tail domain. PTMs modulate both PTEN’s enzymatic activity and cellular locali-
zation. Via phosphorylation of its C-tail, PTEN enters a conformationally closed state, which promotes membrane dissociation. In contrast, mono-ubiquitination
can promote nuclear localization where PTEN may act via phosphatase-dependent or -independent mechanisms. Poly-ubiquitination promotes PTEN
degradation.
Cell Chemical Biology
PerspectivePTEN’s PDZ-binding motif at the plasma membrane often
enhance PTEN’s phosphatase activity (e.g., interactions with
DLG1, MAST2, or NHERF1) while PPIs involving PTEN’s C2 or
phosphatase domains are known to repress enzymatic activity
(e.g., PREX2a, SIPL1, orMan2C1 interactions) (Worby andDixon,
2014). In the nucleus, PTEN-mediated PPIs enhance the activity
of numerous protein substrates such as the kinetochore-binding
protein CENP-C, the E3 ubiquitin ligase APC/C as well as p53
(Worby and Dixon, 2014). In general, these nuclear interactions
have been shown to benefit chromosomal stability and healthy
cell-cycle progression (Worby and Dixon, 2014). However, it re-
mains unclear whether PTEN’s phosphatase activity acts in con-
cert with these effects.
Themodulation of PTEN activity and/or protein levels is consid-
ered a potential therapeutic strategy for a number of disease
states. To describe the overall amount of PTEN capable of
engaging in both phosphatase-dependent and -independent ac-
tivities, the term ‘‘functional dose’’ has been introduced (Berger
et al., 2011). Given PTEN’s central role in the regulation of cell
growth and proliferation, changes to its functional dose trigger
profound biological effects that are expected to be of therapeutic
use (Figure 2) (Alimonti et al., 2010). A reduction of PTEN’s func-
tional dose can promote cell growth and proliferation and is
considered beneficial in regenerative medicine, e.g., after stroke
or ischemia, and in Alzheimer’s disease. However, it is not clear
to what extent such strategies may induce cancer formation. On
the other hand, increasing PTEN’s functional dose and thereby
promoting its tumor suppressor activity has been pursued for
the development of anti-cancer therapies, the treatment of certain
forms of autism as well as cancer predisposition syndromes.20 Cell Chemical Biology 25, January 18, 2018In this perspective, we summarize available strategies for both
reduction and increase of functional dose, considering all stages
of PTEN biogenesis from direct protein modulation to the target-
ing of relevant miRNAs as well as the PTEN gene and mRNA
(Figure 2, bottom). In addition, emerging technologies are high-
lighted that could provide valuable, PTEN-targeting strategies.
We conclude with a general discussion of PTEN’s potential as
a therapeutic target and the risks associated with its central tu-
mor suppressor function.
Reduction of PTEN’s Functional Dose
The reduction of PTEN’s functional dose has garnered interest in
the context of tissue regeneration, given PTEN’s central role as an
antagonist of AKT-mediated cell growth and proliferation. In the
nervous systemwhere tissue (re)growth is intrinsically protracted,
conditional PTEN deletion (and subsequentmTOR activation) has
been shown to promote axon regeneration after crush injuries in
both optical and spinal neurons (Liu et al., 2010; Park et al.,
2008; Sun et al., 2011). Analogously, conditional PTEN deletion
benefits cardiomyocyte survival by preventing ischemia and
limiting reperfusion (Bird et al., 2014; Ruan et al., 2009). Collec-
tively, these findings have shaped PTEN’s profile as a therapeutic
target after stroke and nerve injuries. PTEN dose reduction may
also find application in the context of Alzheimer’s disease. As
recently shown, PTEN silencing or inhibition of PTEN membrane
localization at synapses affected by b-amyloid aggregation leads
to strong reductions in Alzheimer-mediated cognitive deficiencies
(Knafo et al., 2016). Approaches to reduce PTEN’s functional
dose involve direct protein inhibition, the targeting of PTEN
mRNA, and anti-gene strategies (Figure 2).
Figure 2. Overview of Potential Therapeutic
Applications and Strategies Toward PTEN
Modulation
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PTEN is translated as a 403 residue protein comprised of a cen-
tral phosphatase and C2 domain flanked by flexible regulatory
tails (Figure 3A) (Lee et al., 1999). The phosphatase domain har-
bors a highly conserved active site around the catalytic cysteine
(C124) within the canonical phosphate-binding loop (P loop: [I/V]
HCXXGXXR[S/T]) (Figure 3B) (Lee et al., 1999). Together with its
neighboring C2 domain, the phosphatase domain bares a num-
ber of surface exposed lysine and arginine residues which facil-
itate PTEN’s association to the plasma membrane (Figure 3A)
(Song et al., 2012). Other binding sites include a PIP2 recognition
region within PTEN’s N-tail and a PDZ-binding motif at the C ter-
minus (Campbell et al., 2003; Lee et al., 1999). So far, two stra-
tegies have been pursued to directly reduce PTEN’s functional
dose: (1) inhibition of PTEN’s phosphatase activity and (2) inhibi-
tion of PTEN PPIs.
Inhibition of Phosphatase Activity. Similar to other protein tyro-
sine phosphatases (PTPs), PTEN has proven a challenging
target with only a small number of inhibitors so far developed
(Fahs et al., 2016; Stanford and Bottini, 2017). Early PTEN inhib-
itors originated from a screen of bisperoxidovanadium (bpV)
complexes with promiscuous PTP inhibitory activities (Sal-
mena, 2016). Of these, complexes such as bpV-OHpic
(Figure 3C) exhibit selectivity for PTEN above PTP-b and
PTP-1B, resulting in activation of AKT-dependent signaling in
cell-based assays (Schmid et al., 2004). Subsequently, bpV
complexes were utilized in a number of in vivo studies to inhibit
PTEN and induce mTOR-mediated axon regeneration (Christie
et al., 2010; Walker and Xu, 2014; Wu et al., 2013). Mechanisti-
cally, these complexes act via oxidation of PTEN’s catalytic
cysteine C124 resulting in the formation of a disulfide bond
with closely aligned cysteine C71 (Figure 3D) (Lee et al.,
2015). This oxidation is reversible and results in the formation
of orthovanadate, which is known to inhibit various other humanCellenzymes (Costa Pessoa et al., 2015). Va-
nadyl (VO) complexes such as VO-OHpic
(Figure 3C), have also been shown to
inhibit PTEN phosphatase activity
in vitro (half maximal inhibitory concen-
tration, 35 nM) while triggering increased
PIP3 levels and AKT translocation in NIH
3T3 fibroblasts (Rosivatz et al., 2006).
Unlike bpVs, VO complexes are sug-
gested to inhibit phosphatases through
a reversible, non-oxidative mechanism,
a feature recently exploited for activity-
based, phosphatase imaging probes
(Collins et al., 2016). Aside from vana-
dium-based complexes, SF1670 and
the napthoquinone-derived natural prod-
uct Shikonin have been reported to
inhibit PTEN’s phosphatase activity
(Figure 3E), likely through irreversiblemechanisms of action (Garlich et al., 2005; Nigorikawa et al.,
2006; Spinelli et al., 2015).
Inhibition of Protein-Protein Interactions. Inhibiting PPIs has
also been explored to reduce PTEN functional dose. For this pur-
pose, antagonistic molecules have been derived from PTEN
itself. Esteban and co-workers synthesized amembrane-perme-
able variant of PTEN’s PDZ-binding motif which they found to
block post-synaptic PTEN membrane localization and reduce
AKT/GSK3b-directed signaling in Alzheimer’s mouse models
(Knafo et al., 2016). Similarly, PDZ-derived peptide antagonists
were capable of blocking MAST2-PTEN interactions (Terrien
et al., 2012). In addition, other peptides derived from PTEN’s
phosphatase domain and C-tail have been found to positively in-
fluence axon growth and recovery in mice affected by spinal
injury (Ohtake et al., 2014). Despite these results, the PTEN spec-
ificity of thesemolecules is intrinsically limited due to the ubiquity
of PDZ motifs and recognition elements (Lee and Zheng, 2010).
Alternatively, antagonists derived from PTEN interaction part-
ners have been reported such as 3L4F, a truncated peptide
from an intracellular loop of the 5-HT2C receptor (5-HT2CR),
which was found to prevent PTEN-5-HT2CR complex formation
and to decrease PTEN-mediated dephosphorylation both
in vitro and in vivo (Anastasio et al., 2013; Ji et al., 2006).
Targeting PTEN mRNA and PTEN Gene Editing
Inhibition of PTEN biogenesis has been mainly pursued using
antisense oligonucleotides (ASOs). Comprised of DNA or non-
natural analogs, ASOs target complementary mRNA strands
through Watson-Crick base-pairing to prevent translational pro-
cessing and/or induce nuclease-mediated degradation (Li and
Rana, 2014). Initially reported ASOs targeting PTEN mRNA
were comprised of phosphorothioate backbones and 20-O-me-
thoxy-ethyl (MOE)-modified ribonucleotides, which displayed
strong biological profiles, reducing PTEN protein expression by
up to 90% in mouse liver tissues (Butler et al., 2002). FurtherChemical Biology 25, January 18, 2018 21
Figure 3. Inhibition of PTEN Phosphatase
Activity
(A) Schematic overview of PTEN’s structure
(derived from crystal structure PDB: 5BZZ) (Lee
et al., 2015).
(B) Close up of PTEN’s active site not showing a
tartrate molecule originating from crystallization
buffer (PDB: 5BZZ) (Lee et al., 2015).
(C) Selection of bpV and VO complexes exhibiting
PTEN phosphatase inhibition.
(D) Close up of PTEN’s active site after bpV-
mediated disulfide bridge formation (PDB: 5BUG)
harboring orthovanadate (Lee et al., 2015).
(E) Chemical structures of PTEN inhibitors.
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greater potency but also led to hepatotoxicity in vivo (Swayze
et al., 2007). Aside from ASOs, the therapeutic application of
RNAi strategies (e.g., short interfering RNA [siRNA] and short
hairpin RNA [shRNA]) has been explored with the support of
specialized delivery modalities (Kanasty et al., 2013; Krishna-
murthy et al., 2008). In one example, the use of lipopeptide nano-
particles allowed for the targeted delivery of PTEN-specific
siRNAs to liver hepatocytes in mice, where PTEN expression
levels were reduced by up to 80% (Dong et al., 2014). In the22 Cell Chemical Biology 25, January 18, 2018case of PTEN-targeting shRNA, delivery
via tyrosine-mutated adeno-associated
virus (AAV) vectors induced mTOR-medi-
ated axon regeneration in rat optic nerves
(Huang et al., 2017).
Finally, rather than targeting PTEN’s
gene products, proof-of-principle studies
to directly inhibitPTEN transcription (anti-
gene strategies) have been reported (Cox
et al., 2015; Gutilla and Steward, 2016).
By flanking PTEN with LoxP sequences,
He and co-workers deleted PTEN in
mouse sensimotor cortices using an
AAV-Cre-mediated system to induce
mTOR-mediated corticospinal regenera-
tion after injury (Liu et al., 2010). Notably,
even after long-term (>12 months) PTEN
deletion, cortical neurons displayed
healthy phenotypes and did not display
tumorigenesis (Gutilla et al., 2016).
Reduction of PTEN Dose:
Conclusions and Outlook
The design of selective and potent PTEN
inhibitors remains an unresolved issue in
drug discovery. Similar to other PTPs,
this is mainly due to the highly polar na-
ture of PTEN’s active site, which ham-
pers the development of cell-permeable
inhibitors (Stanford and Bottini, 2017).
For that reason, it is not surprising that
reported PTEN inhibitors often follow a
covalent and rather unselective mode
of action involving the targeting of
cysteine 124. Building on the susceptibil-
ity of this cysteine, covalent fragment-based screening could be envisioned to identify more selective,
irreversible inhibitors (Kathman et al., 2014; Ruddraraju and
Zhang, 2017). Recent examples of allosteric and bivalent PTP
inhibitors that target alternative sites may also open new op-
tions for the development of selective PTEN inhibitors (Zhang,
2017). Separately, the disruption of PTEN PPIs has shown po-
tential in providing ameans to selectively inhibit PTEN in defined
disease contexts, potentially allowing for intervention with spe-
cific functions rather than the entire PIP3-dependent signaling
network. While preliminary examples have mainly focused on
Cell Chemical Biology
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inhibitors should provide analogs with higher bioactivity (Pe-
lay-Gimeno et al., 2015). In this respect, macrocyclic structures,
derived from irregular loop-like binding epitopes are particularly
interesting (Glas et al., 2014; Wiedmann et al., 2017). Address-
ing the low cellular uptake of peptide-derived structures, les-
sons learned from cell-penetrating peptides (Brock, 2014; Die-
trich et al., 2017) or strategies that use smaller ligands that only
form the product upon target engagement should be consid-
ered (Brauckhoff et al., 2014; Jaegle et al., 2017). To fully eval-
uate the potential of such strategies, a more detailed investiga-
tion of PTEN’s interactome is required. In this context, the use of
mixed modalities or the stabilization of certain PTEN PPIs could
provide novel probes or potentially more selective agents (Thiel
et al., 2012; Valeur et al., 2017). On a translational level, ASOs
and RNAi strategies that target PTENmRNA have proven useful
for the modulation of PTEN’s functional dose. However, well-
documented delivery issues associated with these techniques
are the main limiting factor for broader applications (Dowdy,
2017). Finally, the rise of novel gene editing techniques such
as CRISPR/Cas 9, C2c2, or Cpf1 could offer potentially very effi-
cient access to PTEN depletion in a tissue-specific manner pro-
vided that current delivery and selectivity issues have been ad-
dressed (Nakade et al., 2017).
Increase of PTEN’s Functional Dose
PTEN is a quasi-insufficient tumor suppressor referring to the
fact that partial PTEN inactivation can already promote tumori-
genesis (Carracedo et al., 2011). PTEN inactivation is seen in a
variety of cancers with COSMIC listing over 3,000 PTEN muta-
tions in 30 different tissue types. The bulk of these somatic mu-
tations either disable PTEN’s active site or alter its C2 domain to
prevent membrane binding (Forbes et al., 2015). Therefore,
increasing or re-instating PTEN’s functional dose has been pro-
posed as an anti-cancer strategy. Increasing its functional dose
may also find application in other diseases related to PTEN
inactivation, such as certain forms of autism or autism spectrum
disorders where germline mutations in PTEN lead to increased
synapse growth, manifesting in synaptic hyperactivity and excit-
ability (Takeuchi et al., 2013; Knafo and Esteban, 2017). PTEN
germline mutations can also lead to cancer predisposition syn-
dromes such as Cowden disease, Bannayan-Riley-Ruvalcaba
syndrome and Proteus syndrome (Arch et al., 1997; Hollander
et al., 2011; Liaw et al., 1997). For that reason, increasing its
functional dose is expected to benefit such patients. An increase
of PTEN’s functional dose is a particularly challenging endeavor,
and depending on the disease context, this may require different
strategies. So far, PTEN protein delivery, miRNA targeting, and
gene editing have been pursued (Figure 2).
PTEN Protein Delivery
Besides antibodies, peptides, and hormones, a growing list of
protein-based therapeutics have received regulatory approval
in recent years (Kinch, 2015). While many issues have been over-
come, therapeutic protein delivery remains challenging due to
degradation and low membrane permeability (Mitragotri et al.,
2014). Nonetheless, some studies indicate that the intracellular
delivery of certain PTEN variants may be feasible. In one such
approach, exogenous introduction of PTEN, functionalized with
cationic lipidoid nanoparticles, promoted apoptosis of PTEN-null, prostate cancer cells (PC-3) via the antagonism of AKT
signaling (Altinoglu et al., 2016). Fluorescence microscopy of
labeled PTEN nanoparticles confirmed intracellular delivery (Alti-
noglu et al., 2016). Similarly, it was found that silica nanoparticles
also promote PTEN’s cellular uptake (Arora and Ghosh, 2016).
Alternatively, it was reported that a cell-permeable, translational
variant of PTEN (PTEN-long) can inhibit PI3K signaling and
induce tumor cell apoptosis in vitro as well as regression of
PTEN-null xenograft tumors in mice (Hopkins et al., 2013).
Inhibition of PTEN-Targeting miRNAs
As PTENmRNA is subject to translational repression by a host of
miRNAs, miRNA inhibition provides a route to increase PTEN’s
functional dose. miRNAs are short, non-coding RNAs that are
transcribed as part of large stem-loop-containing pri-miRNAs
(Figure 4A). Pri-miRNAs are recognized by the RNase Drosha to
provide smaller, hairpin-like sequences known as pre-miRNAs
(Figure 4A). Upon nuclear export, pre-miRNAs undergo cleavage
via the RNaseDicer to generatematuremiRNAduplexes of ca. 21
bases in length with short unpaired terminal sequences
(Figure 4A). One of the two strands of mature miRNA (guide
strand) is then incorporated into the RNA-induced silencing com-
plex (RISC) to recognize complementary or closely relatedmRNA
sequences to block translation and/or promote mRNA degrada-
tion (Figure 4A) (Bartel, 2009; Lin and Gregory, 2015). RISC-asso-
ciated miRNAs often recognize multiple mRNA targets due to
their short length. Resultantly, many PTEN-targeting miRNAs
also regulate other genes: e.g., miR-19 (BIM, BCL2, Prkaa2),
miR-21 (PDC4, RECK, TPM1), and miR-221 (BMF, BBC3/
PUMA, CDKN1B) (Krichevsky and Gabriely, 2009; Lupini et al.,
2013; Mavrakis et al., 2010). In cancer, aberrantly transcribed
miRNAs that dysregulate the mRNA of tumor suppressors and
oncogenes have been termed oncomiRs (Esquela-Kerscher and
Slack, 2006). One such oncomiR is the PTEN-targeting, miR-21,
implicated in the progression of hepatocellular cancer, lung
cancer, and colorectal cancer (Meng et al., 2007; Xiong et al.,
2014; Zhang et al., 2010). miR-21 is a prime target for therapeutic
application and its inhibition has been pursued intensively. For
that reason, we focus here on miR-21 targeting as a means of
increasing PTEN’s functional dose.
Direct Inhibition of Mature miR-21. To target mature miR-21
guide strands (red in Figure 4B), a number of antisense oligonu-
cleotides have been developed and are referred to as anti-miR-
21s (Li and Rana, 2014). Following initial reports of 20-OMe
anti-miR-21s (Figure 4C), Isis Pharmaceuticals performed a
comprehensive screen of anti-miR-21 backbone modifications
(Cheng et al., 2005; Davis et al., 2006). While both 20-O-Me
and 20-O-MOE-modified derivatives (Figure 4C) showed compa-
rable miR-21 affinity in biochemical assays, 20-O-MOE anti-miR
exhibited superior, cell-based miR-21 inhibition likely due to its
higher nuclease stability (Davis et al., 2006). In separate studies,
short phosphorothioate-based LNAs (Figure 4C) were used to
engage the seed region of miR-21 with sub-nanomolar affinity
resulting in long-lasting miR-21 inhibition in vivo (Obad et al.,
2011). As a variation on this concept, anti-miR-21s have recently
been assembled using selenomethylene-locked nucleic acids
(SeLNA, Figure 4C) to further improve nuclease stability (Nahar
et al., 2016a, 2016b). While the above-mentioned ASOs block
miR-21, alternative approaches have aimed to degrade miR-21
(Lennox and Behlke, 2011). For this purpose, hybrid anti-miRsCell Chemical Biology 25, January 18, 2018 23
Figure 4. Inhibition of PTEN-targeting miRNAs
(A) miRNA biogenesis and function involving pri- and pre-miRNA precursors that are processed by Drosha and Dicer, respectively.
(B) Sequence of precursor stem loop with mature miR-21 (red) and guide strand highlighted.
(C) Examples of oligonucleotide analogs used to construct miR-21-targeting ASOs.
(D) Chemical structures of miR-21 targetingmolecules including NMR structure of L50 bound to truncated pre-miR-21 (30 nt, PDB: 5UZZ) (Shortridge et al., 2017).
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ing blocks have been employed to allow for RNase H degrada-
tion of miR-21 (Davis et al., 2006; Lennox and Behlke, 2010).
In addition, catalytically active oligonucleotides have been
developed that are capable of cleaving complementary single-
stranded RNA. For example, hammerhead ribozymes were engi-
neered to deplete miR-21 levels in human glioblastoma cells,
resulting in increase of PTEN protein levels (Belter et al., 2016;
Patutina et al., 2017).
Inhibition of miR-21 Maturation. Rather than directly engaging
miRNAs, the inhibition of miRNA maturation has also been
pursued (Schmidt, 2014; Shortridge and Varani, 2015). miRNA
precursors are challenging therapeutic targets, owing to their
flexibility, charged character, and lack of atypical ligand recogni-
tionmotifs (Schmidt, 2014). While in principle, anti-miRs (such as
those discussed above) can engage the sequences of miRNA
precursors (e.g., pre-miR-21), they usually exhibit substantially
lower affinities due to the self-complementarity of precursor
hairpin structures. Alternatively, two classes of small molecules
have been identified that display general RNA-binding ten-
dencies. These include saccharide-derived structures that often
target RNA loops as well as bulges, and aromatic scaffolds
that intercalate within RNA duplexes (Thomas and Hergenrother,
2008; Velagapudi and Disney, 2013). For pre-miR-21 (Figure 4B),
binding by bioactive aminoglycosides such as streptomycin,
neomycin, and kanamycin has been reported, showing relatively
low inhibition of Dicer cleavage (Bose et al., 2012; Yan et al.,
2017). To increase potency, bifunctional derivatives combining
pre-miR-21 binder neomycin with a small-molecule inhibitor of24 Cell Chemical Biology 25, January 18, 2018Dicer have been developed. By virtue of conjugation, the
neomycin derivative 7a (Figure 4D) saw an increase in Dicer inhi-
bition by more than two orders of magnitude and was capable of
selectively reducing miR-21 levels in cell-based assays (Yan
et al., 2017). Alternatively, small-molecule screening campaigns
for pre-miR-21 binders or maturation inhibitors have proven
feasible, yielding a few relatively low affinity tool compounds
(Connelly et al., 2017; Gumireddy et al., 2008; Naro et al.,
2015; Shi et al., 2013). In one recent example, a microarray
screen of 20,000 compounds provided comp13 (Figure 4D),
which displays low micromolar affinity for pre-miR-21 and was
found to inhibit Dicer cleavage in biochemical assays (Connelly
et al., 2017).
To inhibit challenging biological targets such as pre-miRNA,
peptides have recently attracted attention due to their large bind-
ing surfaces and unique conformational propensities (Pai et al.,
2012). Using phage display, a linear, 12-mer peptide (peptide-1,
Figure 4D) with high affinity for pre-miR-21 (Kd = 13 nM) was
found to inhibit Dicer processing in cell-based assays while
also upregulating PTEN expression (Bose et al., 2015). In a sepa-
rate study, mirror-image phage display of disulfide bridged pep-
tides against pre-miR-21 was performed to address the inherent
protease susceptibility of peptides. In this setup, L-peptides are
screened against ‘‘mirror’’ RNA (L-enantiomer of RNA) with cor-
responding hit sequences then used as templates for D-peptides
to bind natural D-RNA. In the case of pre-miR-21, this approach
generated D-peptide-7 (Figure 4D), which displayed moderate
affinity for pre-miR-21 in biochemical assays (Sakamoto et al.,
2017). Recently, pre-miR-21 was also screened against a small
Cell Chemical Biology
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bovine immunodeficiency virus Tat sequence. Using electromo-
bility shift assays, cyclic peptide L50 (Figure 4D) was identified
and later characterized as a selective, high-affinity pre-miR-21
binder (Kd = 0.2 mM). In addition to inhibiting Dicer cleavage
in vitro, a nuclear magnetic resonance (NMR) structure of
pre-mir-21 in complex with peptide L50 was elucidated
(Figure 4D). Interestingly, L50 binds to the major groove of the
stem region adjacent to the apical loop thereby blocking sites
of Dicer cleavage (Shortridge et al., 2017).
PTEN Gene Introduction
One final strategy that has briefly been described toward
increasing PTEN’s functional dose is PTEN gene introduction.
First reported by Tanaka et al. in 2000, PTEN was exogenously
introduced via an adenoviral vector into PTEN-null human
bladder cancer cells where it was found to suppress tumor cell
growth through the abrogation of AKT signaling (Tanaka et al.,
2000). Subsequent studies involving human colorectal and pros-
tate cancer cells yielded similar results (Saito et al., 2003; Tanaka
et al., 2005). Moreover, for human bladder and colorectal cancer,
gene editing successfully reduced tumor growth in xenograft
mice (Saito et al., 2003; Tomioka et al., 2008). Notably, the intro-
duction of additional PTEN genes into cells with physiological
PTEN levels had only little effect, supporting the therapeutic
applicability of this approach (Tanaka and Grossman, 2003).
Even more remarkably, mice with systemically elevated PTEN
(‘‘Super-PTEN’’ mutants) display healthy phenotypes and are
characterized with heightened resistance to cancer (Garcia-
Cao et al., 2012).
Increase of PTEN Dose: Conclusions and Outlook
Overall, increasing PTEN functional dose represents an alterna-
tive to inhibitors of PI3K (responsible for PIP3 production at the
membrane), AKT, or mTOR, most of which have faced efficacy
issues related to therapeutic resistance (Porta et al., 2014).
Oneway to achieve PTEN dose increase could involve the devel-
opment of PTEN agonists or molecules that activate pathogenic
PTEN variants. As shown for the discovery of allosteric SHIP-1
phosphatase activators, the screening of natural product li-
braries against PTEN could provide a novel source of such com-
pounds (Ong et al., 2007). Another plausible PTEN activation
strategy involves the design of bifunctional compounds to
localize PTEN at the plasma membrane (Stiller et al., 2017)
thereby promoting its phosphatase activity. As the case for pro-
tein delivery has beenmade above, engineered variants of PTEN
with enhanced phosphatase activity, such as the recently re-
ported ePTEN (Nguyen et al., 2014), may support a therapeutic
application.
In regard to direct miR-21 targeting, the full breadth of avail-
able DNA analogs (e.g., PNA and moropholinos) has yet to be
explored and can yield novel ASO-based inhibitors (van Rooij
and Kauppinen, 2014). To circumvent the delivery issues associ-
ated with ASOs, however, the targeting of miRNA maturation is
becoming increasingly investigated. With respect to small mole-
cules, the utilization of dynamic combinatorial libraries or cova-
lent inhibitor strategies can be expected to facilitate the discov-
ery of novel pre-miR-21 ligands in the future (Connelly et al.,
2016). Moreover, given recent achievements in phage display
(Pai et al., 2012) and protein design (Chen et al., 2016) it is clear
that peptide-derived structures also hold the potential to provideselective pri- or pre-miR-21 binders. From initial screens, pepti-
domimetics such as peptoid ligands have exhibited suitability for
this purpose (Chirayil et al., 2009; Diaz et al., 2014). The
screening of alternative modalities such as aptamers appears
to show similar promise and may be an alternative source of
novel ligands (Kabza and Sczepanski, 2017). Having focused
on miR-21, additional PTEN-targeting oncomiRs should also
be considered and used to probe the suitability of miR-21 in
the context of its other targets. Finally, with respect to gene ther-
apy, many hurdles need to be overcome with regard to unde-
sired immunogenicity and non-specific genetic modification
(Kotterman et al., 2015). Once more, recent advances in
CRISPR/Cas 9 gene editing and other systems provide a poten-
tially powerful platform to correct for somatic PTEN mutations.
However, considerable efforts are still required before such
techniques see widespread therapeutic applications (Dai et al.,
2016; Nakade et al., 2017; Xue et al., 2014).
Concluding Remarks
It is now 20 years since PTEN’s discovery. Within the first
decade, many fundamental insights into PTEN’s phosphatase
activity, its structure, and tumor suppressor function were
pieced together. Passing into the second decade, large strides
were made in understanding the extent and subtleties of PTEN
regulation from the transcriptional level to PTMs. Having all these
insights available, still many more questions regarding PTEN
biology remain to be answered, e.g., What are the precise,
nuclear roles of PTEN? How do phosphatase independent func-
tions contribute to its tumor suppressor activity? What is the
biological significance of PTEN’s growing list of isoforms and
translational variants? To what degree does epigenetic regula-
tion affect PTEN functional dose? How is PTEN dose affected
by oncomiR networks?
The third decade can be expected to elucidate these remain-
ing aspects of PTEN biology but also to contribute therapeuti-
cally relevant targeting strategies. In this respect, it is essential
to identify disease contexts in which PTEN targeting is systemi-
cally tolerated. Particularly in regard to reducing its functional
dose, PTEN’s ‘‘risky’’ profile as a tumor suppressor has to be
considered. While recent studies suggest a possible therapeutic
window for PTEN dose reduction without triggering tumorigen-
esis, dysfunctional outcomes of PTEN deletion in the past have
raised questions over its therapeutic suitability (Gutilla et al.,
2016; Liu et al., 2010; Pun et al., 2012; Williams et al., 2015).
To address these issues, potent and selective inhibitors are
required that allow selective, short-term PTEN inhibition prefer-
ably in a tissue-specific manner. In our view, such compounds
will likely arise from protein- or mRNA-targeting approaches. In
particular, when considering the availability of new targeting
paradigms such as selective ribosomal inhibitors, spliceosome
inhibitors, or targeted protein degradation approaches (e.g.,
PROTACS) (Cromm and Crews, 2017; León et al., 2017; Lintner
et al., 2017). Undoubtedly, increasing PTEN’s functional dose is
of prime interest as an anti-cancer strategy but is also extremely
challenging, mainly due to a lack of PTEN-activating agents and
general shortcomings related to miRNA targeting. It can be ex-
pected that all levels of PTEN biogenesis and regulation must
be taken into consideration when aiming for therapeutically rele-
vant PTEN dose reduction. In addition, it remains to be seen ifCell Chemical Biology 25, January 18, 2018 25
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Perspectivecertain oncogenic PTEN variants are tractable as drug targets
themselves, and if PTEN’s post-translationally modified deriva-
tives can be selectively modulated.
Taken together, we can conclude that PTEN is certainly an
intriguing therapeutic target but that more efforts are required
to define relevant indications both for an increase and a reduc-
tion of PTEN’s functional dose. To address this question, chem-
ical tools are required that allow selective modulation of the
various PTEN functions. This process should be curiosity driven
and consider all options, not only the protein’s phosphatase ac-
tivity, PPIs, and PTMs but also the PTEN gene and mRNA,
including regulating miRNAs. For that reason, it is desirable
that the different subfields move closer together and that result-
ing tool compounds are more rigorously tested in biologically
relevant systems. With that in mind, one can certainly expect
the chemical biology community to provide selective agents
that may finally open up new pathways toward PTEN’s pharma-
cological intervention.ACKNOWLEDGMENTS
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